Amgen Infergen may be marketed as hepatitis C relapse treatment, firm tells analysts.

Executive Summary

AMGEN INFERGEN MARKETING MAY TARGET HEPATITIS C RELAPSERS, statements by Chief Financial Officer Robert Attiyeh at a June 4 Paine Webber analysts meeting in New York City indicated. Attiyeh said that pivotal trials with the drug yielded a "durable response in 58% of the relapsers" who have undergone existing interferon therapy. Infergen (consensus interferon) was deemed "approvable" by FDA in April. "We're simply negotiating the final terms and conditions of the package insert. We expect approval to go to the market later this year," Attiyeh said. Yamanouchi licensed rights to market Infergen in all markets except North America.